Company profile for Dynavax Technologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines. We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet n...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines. We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet needs. Our vision and work ethic are guided by the collective ideals underpinning our corporate values, and these form the basis of our company culture.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2100 Powell Street, Suite 900 Emeryville, CA 94608
Telephone
Telephone
+1.510.848.5100
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/dynavax-to-participate-at-the-8th-annual-evercore-healthcare-conference-302620786.html

PR NEWSWIRE BIO
20 Nov 2025

https://www.prnewswire.com/news-releases/dynavax-reports-third-quarter-2025-financial-results-and-announces-new-100-million-share-repurchase-program-302606025.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/dynavax-enters-exclusive-license-agreement-for-vaxarts-novel-oral-covid-19-vaccine-program-302606056.html

PR NEWSWIRE
05 Nov 2025

https://www.prnewswire.com/news-releases/dynavax-presents-positive-topline-data-from-part-1-of-phase-12-trial-for-shingles-vaccine-candidate-at-idweek-2025-and-announces-initiation-of-part-2-of-trial-302590508.html

PR NEWSWIRE
22 Oct 2025

https://www.prnewswire.com/news-releases/dynavax-to-report-third-quarter-2025-financial-results-and-host-conference-call-on-november-5-2025-302591183.html

PR NEWSWIRE
22 Oct 2025

https://www.prnewswire.com/news-releases/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540380.html

PR NEWSWIRE
27 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty